Evaluation – Questions & answers
[expand title=”Cite the main two molecules whose signaling domains mediate co-stimulation of CAR-T cells.” tag=”strong”]CD28, 4-1BB[/expand] [expand title=”What is the main difference between conventional T cells and CAR-T cells regarding the recognition of their cognate antigen?” tag=”strong”]
Recognition of antigen by conventional T cells is HLA-restricted, in contrast to CAR-T cells that recognize native membrane antigen independently of HLA. [/expand] [expand title=”How are CAR-T cells produced?” tag=”strong”]
CAR-T cells are T cells that have been genetically-engineered by use of a viral vector (gamma-retroviral for YESCARTA™ and TECARTUS™, lentiviral for KYMRIAH™) so as to express a CAR molecule.[/expand] [expand title=”What is the main cytokine responsible for the cytokine release syndrome (CRS) after CAR-T cell therapy?” tag=”strong”]
interleukin-6 (IL-6)[/expand] [expand title=”What is the main biological drug used to treat the CRS after CAR-T cell therapy?” tag=”strong”]
Tocilizumab, a therapeutic antibody directed to the receptor of interleukin-6 (IL-6)[/expand]
